ReviewNature reviews. Drug discovery2015
A holistic approach to targeting disease with polymeric nanoparticles.
Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed.
- Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects.Drug delivery and translational research · 2019Trial
- Amphipathic peptoid transporters for protein and nanoparticle delivery.RSC advances · 2026Article
- Reactive Flash Nanoprecipitation: Expanding the Landscape of Nanoparticle Fabrication for Biomedical Applications.International journal of polymeric materials · 2026Article
- Engineered Cell Membrane-Coated Nanoparticles: A New Strategy for Pancreatic Cancer Therapy.ACS pharmacology & translational science · 2026Review
- Spatiotemporal precision interventions for cardiac repair and regenerative therapy.Experimental & molecular medicine · 2026Review
- Bridging cancer therapies: the role of magnetic nanoparticles in combination cancer therapy.Discover nano · 2026Review
- Molecular Simulations of Polymer-based Drug Nanocarriers: From Physical and Structural Properties to Controlled Release.Advanced healthcare materials · 2026Review
- Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis.Nature communications · 2025Article
- Article
- The future of cardiac repair: a review on cell-free nanotherapies for regenerative myocardial infarction.Drug delivery and translational research · 2025Review
- Magnetic mesoporous silica nanoparticles as advanced polymeric scaffolds for efficient cancer chemotherapy: recent progress and challenges.RSC advances · 2025Review
- Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025Review
- Targeting Polymeric Nanoparticles to Specific Cell Populations in the Liver.Biochemistry · 2025Review
- The Emergence of Nanotechnology in the Prognosis and Treatment of Myocardial Infarctions.Recent patents on nanotechnology · 2025Review
- Therapeutic Vaccination in Lung Cancer: Past Attempts, Current Approaches and Future Promises.Journal of respiratory biology and translational medicine · 2025Article
- Safety Profile of Intravenous Ferulic Acid Nanoparticles: Acute Toxicity and Neurological Effects in Sprague-Dawley Rats.Nanotechnology, science and applications · 2025Article
- Biological and Bioinspired Vesicles for Wound Healing: Insights, Advances and Challenges.International journal of nanomedicine · 2025Review
- Advanced Drug Delivery Systems: From Microsponges to Nanotechnologies.Recent advances in inflammation & allergy drug discovery · 2025Article
- Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma.Advanced nanobiomed research · 2024Article
- Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.Drug delivery and translational research · 2024Review
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this field has matured, the notion of targeting has been minimized to the concept of increasing the affinity of a nanoparticle for its target. This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously. This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.